SMAD3 and neoplasm: Our most important finding was the identification of some host SMAD3 genetic polymorphisms (rs744910, rs745103) and SMAD3 protein expression in pre-treatment tumor tissue as predictive markers of response to neoadjuvant treatment in LARC.